Johnson & Johnson (JNJ) Cash & Current Investments (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Cash & Current Investments came in at $20.8 billion in Q2 2026, up 9.95% year-over-year from $18.9 billion in Q2 2025, and down 5.86% quarter-over-quarter from $22.1 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Cash & Current Investments (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Cash & Current Investments across 18 years of filings, most recently posting $20.8 billion for Q2 2026.
- In Q2 2026, Cash & Current Investments rose 9.95% year-over-year to $20.8 billion; the TTM figure through Jun 2026 stood at $20.8 billion (up 9.95% YoY), while the FY2025 annual figure was $20.1 billion, down 18.02% from the prior year.
- Cash & Current Investments came in at $20.8 billion for Q2 2026 at Johnson & Johnson, down from $22.1 billion in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $38.8 billion in Q1 2025 to a low of $18.6 billion in Q3 2025.
- Average Cash & Current Investments over 5 years is $25.6 billion, with a median of $24.5 billion recorded in 2024.
- Year-over-year, Cash & Current Investments surged 47.92% in 2025 and slumped 43.14% in 2026.
- Over 5 years, Cash & Current Investments stood at $34.1 billion in 2022, then tumbled by 32.72% to $22.9 billion in 2023, then gained by 6.96% to $24.5 billion in 2024, then fell by 18.02% to $20.1 billion in 2025, then rose by 3.26% to $20.8 billion in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $20.8 billion in Q2 2026, $22.1 billion in Q1 2026, and $20.1 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 20.76 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 7.14 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 7.69 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 11.70 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 11.07 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 7.38 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 5.10 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 4.54 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 20.76 Bn |
| Mar 29, 2026 | 22.05 Bn |
| Dec 28, 2025 | 20.10 Bn |
| Sep 28, 2025 | 18.56 Bn |
| Jun 29, 2025 | 18.88 Bn |
| Mar 30, 2025 | 38.78 Bn |
| Dec 29, 2024 | 24.52 Bn |
| Sep 29, 2024 | 20.30 Bn |
| Jun 30, 2024 | 25.48 Bn |
| Mar 31, 2024 | 26.22 Bn |
| Dec 31, 2023 | 22.93 Bn |
| Oct 1, 2023 | 23.51 Bn |
| Jul 2, 2023 | 28.51 Bn |
| Apr 2, 2023 | 24.61 Bn |
| Jan 1, 2023 | 22.28 Bn |
| Oct 2, 2022 | 34.08 Bn |
| Jul 3, 2022 | 32.57 Bn |
| Apr 3, 2022 | 30.39 Bn |
| Jan 2, 2022 | 31.61 Bn |
| Oct 3, 2021 | 31.00 Bn |